AIA
NBIX icon

Avalon Investment & Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Avalon Investment & Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,804
Closed -$366K – 343
2020
Q3 		$366K Buy
+3,804
New +$440K 0.01% 286

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avalon Investment & Advisory's NBIX Position: Q4 2020 in Review

Avalon Investment & Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 3,804 shares — an estimated $366K sold.

Avalon Investment & Advisory first reported a position in NBIX in Q3 2020 and held it in 1 quarter. The position peaked at $366K in Q3 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Avalon Investment & Advisory reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Avalon Investment & Advisory sold 3,804 Neurocrine Biosciences shares in Q4 2020, an estimated $366K.
  • Avalon Investment & Advisory first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 1 quarter.
  • Avalon Investment & Advisory's Neurocrine Biosciences position peaked at $366K in Q3 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Avalon Investment & Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.